United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Is Pfizer stock a buy or a sell after the company announced its $43 billion plan to buy Seagen? Is PFE stock a buy or a sell?

Is Pfizer Stock A Buy Or A Sell On Its Looming $43 Billion Seagen Takeover?

A Food and Drug Administration committee is set to meet Thursday to decide whether the regulator should grant full approval to Paxlovid, the antiviral pill developed by Pfizer PFE to treat high-risk COVID infections. The FDA in late 2021 authorized the drug, which generated $18.9 billion in sales in 2022.

FDA panel to meet Thursday to discuss full approval of Paxlovid

Pfizer has had a string of good news in recent weeks, including several positive regulatory decisions. These positive developments seem to be underappreciated by investors.

Here's Why Pfizer Stock Is Looking Increasingly Attractive

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

On March 13, 2023, Pfizer, Inc. (NYSE: PFE) announced it was merging with Seagen Inc. (NASDAQ: SGEN). Under terms of the definitive agreement, Pfizer will buy Seagen for $229 in cash per share.

Pfizer's Latest Acquisition Strengthens the Case for PFE Stock

Royalty Pharma

Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 billion, up from $2.375 billion and $2.475 billion previously (excluding transactions announced subsequent to the date of this release), after receiving a $475 million accelerated milestone payment from Pfizer Inc (NYSE:PFE). The buyer of biopharmaceutical royalties said the Pfizer payment follows the US Food and Drug Administration (FDA) approval of Zavzpret (zavegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine.

Royalty Pharma raises FY2023 guidance after $475M Pfizer milestone payment

BioNTech SE

The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third shot should come no sooner than two months after the primary series of three shots.

FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children

Moderna

Novavax

During the Covid-19 pandemic, vaccine stocks shot up on the promise that they could end the lockdowns. Many vaccines were developed, but few were approved.

3 Vaccine Stocks to Watch for Their Post-Pandemic Moves

City Office REIT

Kellogg

Medtronic

Newmont Mining

Rio Tinto plc Sponsored

Vale S.A.

With markets getting dragged down by another financial crisis, investors should seek safety.  In fact, one of the best places for that is in undervalued dividend stocks.

7 Undervalued Dividend Stocks for Your Must-Buy List

The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.

FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5

Seagen

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

FDA staff said Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support its use in adults at high risk of progressing to severe disease.

FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults

Pfizer reached a record $100 billion in revenue last year, thanks to its coronavirus portfolio. But a decline in vaccine demand and competition ahead for some of Pfizer's other top products is set to weigh on growth.

Does This Billion-Dollar Deal Solve Pfizer's Biggest Problem?

Pfizer has been a stock in search of a catalyst all year long. The drugmaker's $43 billion acquisition of Seagen probably isn't the catalyst shareholders were hoping for.

Is Pfizer Stock a Screaming Buy After Its $43 Billion Seagen Acquisition?

Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.

Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio

NEW YORK , March 14, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seagen Inc. ("Seagen" or the "Company") (NASDAQ: SGEN) in connection with the proposed acquisition of the Company by Pfizer Inc. (NYSE: PFE).  Under the terms of the merger agreement, the Company's shareholders will receive $229.00 in cash for each share of Seagen owned.

SHAREHOLDER ALERT: Weiss Law Investigates Seagen Inc.

Biopharma acquisitions often come with layoffs and lab shutdowns as smaller companies get absorbed.

How Pfizer's $43 billion acquisition of Seagen could impact the biotech industry in Seattle

NEW YORK , March 13, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seagen Inc. (NASDAQ: SGEN) and its board of directors concerning the proposed acquisition of the company by Pfizer Inc. (NYSE: PFE). Stockholders will receive $229.00 for each share of Seagen stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Seagen Inc.

Costco

D.R. Horton

First Republic

Lennar

SVB Financial Group

Sanofi

Target

Toll Brothers

Walmart

SPDR S&P Homebuilders ETF

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

Pfizer CEO Albert Bourla said it will deliver Seagen's cancer therapy to the world at a scale that hasn't been seen before with its $43 billion acquisition.

Pfizer CEO says it will be able to deliver Seagen's cancer therapy at a scale not seen before with $43 billion deal

Acquiring top biotech assets as other big pharmaceutical companies face a patent cliff was bound to be expensive.

Pfizer Overpays for Seagen, but Who's Counting

Zavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022 acquisition of Biohaven. Zavzpret provides migraine patients access to a fast-acting pain-relief option.

Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret

Pfizer (NYSE: PFE) is buying Seagen Inc. (Nasdaq: SGEN) for $43 billion. These are the details.

Pfizer Buying Seagen For $43 Billion: Details (PFE) (SGEN)

The latest deal comes as Pfizer seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs and decline in demand for its COVID products.

Pfizer to pay $43B for Seagen, boosting cancer drug portfolio

Pfizer is buying Seattle-area biotech giant Seagen in a massive $43 billion deal announced Monday.

News for Pfizer Stock (PFE)